California’s SB 535 Provides Better Access to Biomarker Testing
California’s SB 535 prohibits insurers that already cover biomarker testing from requiring prior authorization for patients with advanced stage cancer.
Read MorePosted by Chris Wolski | Oct 13, 2021 | Miscellaneous, Molecular Diagnostics |
California’s SB 535 prohibits insurers that already cover biomarker testing from requiring prior authorization for patients with advanced stage cancer.
Read MorePosted by Toni Mitchell | Oct 5, 2021 | Prostate, Uncategorized |
New research from a team of scientists — and two specially trained dogs — have scientifically validated man’s best friend can “sniff out” prostate cancer.
Read MorePosted by Toni Mitchell | Oct 1, 2021 | Breast, Lung Cancer, Molecular Diagnostics |
OneOncology and Genentech presented data at a symposium that examined genomic profiling and biomarker testing patterns in community oncology centers.
Read MorePosted by Chris Wolski | Sep 20, 2021 | Lymphoma |
Foresight Diagnostics CEO and CSO Jake Chabon gives an overview of what’s next for liquid biopsy testing, and how it will impact the continuum of care.
Read MorePosted by Toni Mitchell | Sep 20, 2021 | Lung Cancer |
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic.
Read More